Cabaletta Bio Inc.

1.01-0.0500-4.72%Vol 229.34K1Y Perf -85.58%
Jun 24th, 2022 16:00 DELAYED
BID0.9876 ASK1.08
Open1.09 Previous Close1.06
Pre-Market- After-Market1.00
 - -  -0.01 -0.99%
Target Price
14.00 
Analyst Rating
Strong Buy 1.08
Potential %
1.29K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
0.78 
Earnings Rating
Market Cap29.27M 
Earnings Date
4th Aug 2022
Alpha-0.05 Standard Deviation0.23
Beta1.53 

Today's Price Range

0.99251.15

52W Range

0.900014.95

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-1.94%
1 Month
-21.09%
3 Months
-52.36%
6 Months
-76.18%
1 Year
-85.58%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CABA1.01-0.0500-4.72
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.64-0.4529.69
Q04 2021-0.68-0.4927.94
Q03 2021-0.52-0.4513.46
Q02 2021-0.51-0.4511.76
Q01 2021-0.49-0.4116.33
Q04 2020-0.34-0.40-17.65
Q03 2020-0.47-0.3623.40
Q02 2020-0.45-0.3522.22
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.52
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume229.34K
Shares Outstanding28.98K
Shares Float27.51M
Trades Count731
Dollar Volume236.28K
Avg. Volume154.29K
Avg. Weekly Volume164.40K
Avg. Monthly Volume150.41K
Avg. Quarterly Volume148.06K

Cabaletta Bio Inc. (NASDAQ: CABA) stock closed at 1.01 per share at the end of the most recent trading day (a -4.72% change compared to the prior day closing price) with a volume of 229.34K shares and market capitalization of 29.27M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 31 people. Cabaletta Bio Inc. CEO is Steven Nichtberger.

The one-year performance of Cabaletta Bio Inc. stock is -85.58%, while year-to-date (YTD) performance is -73.35%. CABA stock has a five-year performance of %. Its 52-week range is between 0.9 and 14.9499, which gives CABA stock a 52-week price range ratio of 0.78%

Cabaletta Bio Inc. currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 0.28, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -44.84%, a ROC of -47.23% and a ROE of -47.17%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cabaletta Bio Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.52 for the next earnings report. Cabaletta Bio Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Cabaletta Bio Inc. is Strong Buy (1.08), with a target price of $14, which is +1 286.14% compared to the current price. The earnings rating for Cabaletta Bio Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cabaletta Bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cabaletta Bio Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.92, ATR14 : 0.14, CCI20 : -71.32, Chaikin Money Flow : -0.24, MACD : -0.11, Money Flow Index : 35.59, ROC : -19.84, RSI : 37.25, STOCH (14,3) : 25.00, STOCH RSI : 0.46, UO : 31.79, Williams %R : -75.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cabaletta Bio Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (83.33 %)
5 (83.33 %)
5 (83.33 %)
Moderate Buy
1 (16.67 %)
1 (16.67 %)
1 (16.67 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.08
Strong Buy
1.08
Strong Buy
1.08

Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its technology uses chimeric autoantibody receptor T cells that are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies while sparing normal B cells. The firm offers preclinical development for the treatment of muscle-specific kinase myasthenia gravis, mucocutaneous PV, and Hemophilia A with factor VIII, or FVIII, alloantibodies. Its products comprise of DSG3/1-CAART, MuSK-CAART, and FVIII-CAART. The firm's initial focus is on Pemphigus Vulgaris, which is an autoimmune blistering skin disease.

CEO: Steven Nichtberger

Telephone: +1 267 759-3100

Address: 2929 Arch Street, Philadelphia 19104, PA, US

Number of employees: 31

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

54%46%

News

Stocktwits